Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 28Lymphoma, Mantle-Cell 14Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 5Lymphoma 5Leukemia, B-Cell 4Multiple Myeloma 3Lymphoma, B-Cell 3Waldenstrom Macroglobulinemia 2Recurrence 2Pancreatic Neoplasms 2Lymphoma, Follicular 2Lymphatic Diseases 2Leukemia, Prolymphocytic 2Leukemia 2Squamous Cell Carcinoma of Head and Neck 1Part1: Advanced B-cell Malignancies 1Ovarian Neoplasms 1Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Hairy Cell 1Immunoproliferative Disorders 1Immune System Diseases 1Hodgkin Disease 1Hematologic Neoplasms 1Hematologic Diseases 1Heart Failure 1Glioblastoma 1DLBCL 1

Interventions

Rituximab 23Lenalidomide 11Cyclophosphamide 10zanubrutinib 9Bendamustine Hydrochloride 8venetoclax 6ibrutinib 6fludarabine 6parsaclisib 5idelalisib 5ublituximab 4obinutuzumab 4aflibercept 4Prednisone 4pirtobrutinib 3Vincristine 3ME-401 3Doxorubicin 3umbralisib 2tazemetostat 2marizomib 2epratuzumab 2Radioimmunodetection 2voruciclib 1veltuzumab 1varlilumab 1tislelizumab 1tetulomab tetraxetan lu-177 1tafasitamab 1repaglinide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, B-Cell, Marginal Zone × acalabrutinib × Clear all
NCT02180711 2025-10-15

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Acerta Pharma BV

Phase 1/2 Active not recruiting
113 enrolled 19 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡